1. Home
  2. APAM vs NAMS Comparison

APAM vs NAMS Comparison

Compare APAM & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artisan Partners Asset Management Inc.

APAM

Artisan Partners Asset Management Inc.

HOLD

Current Price

$42.03

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$35.83

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APAM
NAMS
Founded
1994
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.1B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
APAM
NAMS
Price
$42.03
$35.83
Analyst Decision
Buy
Strong Buy
Analyst Count
4
10
Target Price
$47.00
$45.80
AVG Volume (30 Days)
429.0K
1.1M
Earning Date
10-28-2025
11-05-2025
Dividend Yield
8.51%
N/A
EPS Growth
2.95
N/A
EPS
3.71
N/A
Revenue
$1,158,234,000.00
$35,243,000.00
Revenue This Year
$8.38
N/A
Revenue Next Year
$6.56
N/A
P/E Ratio
$11.51
N/A
Revenue Growth
8.88
4.91
52 Week Low
$32.75
$14.06
52 Week High
$49.29
$42.00

Technical Indicators

Market Signals
Indicator
APAM
NAMS
Relative Strength Index (RSI) 45.53 44.79
Support Level $40.93 $34.70
Resistance Level $43.06 $42.00
Average True Range (ATR) 0.96 1.99
MACD 0.14 -0.65
Stochastic Oscillator 59.60 19.12

Price Performance

Historical Comparison
APAM
NAMS

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: